Literature DB >> 9929113

Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy.

E Mylonakis1, B P Dickinson, M D Mileno, T Flanigan, F J Schiffman, A Mega, J D Rich.   

Abstract

A human immunodeficiency virus (HIV)-infected individual was first diagnosed with red blood cell aplasia due to B19 parvovirus infection in late 1989. Over the subsequent seven-year period, he received a total of 119 units of red blood cells (RBCs) and intravenous immunoglobulin every 2-3 weeks. In 1996 combination antiretroviral treatment with a protease inhibitor was initiated. He received four more units during the following two months and then required no more transfusions for the subsequent 24 months of follow-up. His CD4 count progressively increased and DNA polymerase chain reaction for parvovirus B19 became undetectable. Aggressive antiretroviral treatment may effectively diminish transfusion requirements among HIV-infected individuals with pure RBC aplasia resulting from parvovirus B19 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9929113     DOI: 10.1002/(sici)1096-8652(199902)60:2<164::aid-ajh16>3.0.co;2-4

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature.

Authors:  P Morelli; G Bestetti; E Longhi; C Parravicini; M Corbellino; L Meroni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

Review 2.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

Review 3.  Viruses and kidney disease: beyond HIV.

Authors:  Meryl Waldman; Vickie Marshall; Denise Whitby; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2008-11       Impact factor: 5.299

4.  Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients.

Authors:  Renata Freire Alves Pereira; Rita de Cássia Nasser Cubel Garcia; Kátia Martins Lopes de Azevedo; Sérgio Setúbal; Marilda Agudo Mendonça Teixeira de Siqueira; Solange Artimos de Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-04       Impact factor: 2.743

Review 5.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.